BRAF and melanoma: Belli and collaborators demonstrated that in melanoma cell lines resistant to both BRAF and MEKi, the SAN and A375 cell lines, which harbor the BRAF-V600 mutation and were initially sensitive to these drugs, resistance was primarily driven by the overexpression of specific TKRs, including EphA2 and DDRs.